Page last updated: 2024-10-30

edaravone and Stroke

edaravone has been researched along with Stroke in 83 studies

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

Excerpt	Relevance	Reference
"This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI)."	9.51	The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction. ( Shen, QQ; Tong, XW; Wang, W; Wu, H, 2022)
" Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined."	9.41	Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. ( Li, LD; Shi, SF; Zhou, Y, 2023)
"This study aimed to explore how butylphthalide and edaravone promote healing in acute stroke, drawing on relevant data, literature, clinical experience, and personal concepts."	9.41	Clinical Efficacy and Short-Term Prognosis of Butylphthalide and Sodium Chloride Injection Compared to Edaravone in the Treatment of Patients with Acute Stroke. ( Wang, X; Yang, D; Zhang, J; Zhang, M, 2023)
"We performed a randomized clinical trial protocol to assess the effectiveness of edaravone for acute stroke."	9.41	Safety and efficacy of edaravone for patients with acute stroke: A protocol for randomized clinical trial. ( Cheng, X; Dou, Z; Jiao, G; Shan, H, 2021)
" Here we analyzed the clinical outcomes of acute ischemic stroke (AIS) patients treated with human urinary kallidinogenase (HUK) or edaravone (Eda) combined with butylphthalide (NBP)."	9.30	Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke. ( Jiang, M; Lu, S; Lyu, Y; Nie, T; Qian, Y; Tang, B, 2019)
"While the addition of low dose chlorpromazine and promethazine to standard of care for acute ischemic stroke did not have any significant improvement in functional outcomes, there were no serious adverse effects."	9.30	Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. ( Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)
"To test the hypothesis that edaravone reduces functional dependence in ischemic stroke patients."	9.22	Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022)
" The aim of this meta-analysis was to determine the efficacy and tolerability of edaravone, with or without thrombolytic therapy, in the treatment of patients with acute ischemic stroke."	9.22	Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. ( Li, GZ; Nie, LY; Ye, XM; Zhao, K; Zhu, GY, 2022)
"A randomized, double-blind, placebo-controlled study was performed to prospectively evaluate the effects of edaravone on acute diabetic stroke patients admitted to our hospital within 24 h of stroke onset."	9.22	Edaravone offers neuroprotection for acute diabetic stroke patients. ( Chen, X; Zheng, J, 2016)
"Two new neuro-protective agents, Edaravone and Citicoline were recently found to be beneficial in acute ischemic stroke (AIS)."	9.16	Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012)
"The aim of the present study was to investigate whether administration of edaravone during t-PA infusion can enhance early recanalization in acute stroke patients."	9.16	Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study. ( Aoki, J; Iguchi, Y; Inoue, T; Kimura, K; Kobayashi, K; Sakai, K; Sakamoto, Y; Shibazaki, K, 2012)
" In this study, the temporal profile of ischemic stroke lesion sizes was assessed for more than one year to evaluate the effect of edaravone which might reduce ischemic damage."	9.15	Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. ( Nakase, T; Suzuki, A; Yoshioka, S, 2011)
"Edaravone, a free radical scavenger approved by the Japanese Ministry of Health, Labor and Welfare in 2001 for treating acute ischemic stroke, was recommended by the Japanese Guidelines for the Management of Stroke 2004."	9.14	Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). ( Kobayashi, S; Saito, I; Shinohara, Y; Uchiyama, S, 2009)
"Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients."	9.14	Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010)
"Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients."	9.12	Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis. ( Chen, LQ; Guan, B; Li, Y; Ming, Q; Yang, DX; Yu, D, 2021)
"The efficacy of hyperbaric oxygen (HBO) therapy combined with intravenous edaravone (free radical scavenger) administration was prospectively investigated in patients with acute embolic stroke involving the anterior cerebral circulation."	9.12	Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial. ( Imai, K; Izumoto, H; Kunieda, T; Mori, T; Takabatake, N; Watanabe, M, 2006)
"To assess the effectiveness of edaravone for acute stroke including ischemic stroke and intracerebral hemorrhage (ICH)."	8.91	Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. ( Cui, X; Li, J; Liu, M; Yang, J; Zhang, C; Zhang, J, 2015)
"To assess the efficacy and safety of edaravone for acute ischaemic stroke."	8.87	Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011)
"Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually."	8.86	A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010)
"To investigate the efficacy of butylphthalide combined with edaravone in the treatment of acute ischemic stroke and the effect on serum inflammatory factors."	8.31	Efficacy of Butylphthalide in Combination with Edaravone in the Treatment of Acute Ischemic Stroke and the Effect on Serum Inflammatory Factors. ( Hong, Z; Li, S; Li, Y; Liu, Y; Wang, J; Xie, S, 2023)
"DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment."	8.31	A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023)
"For investigating an influence on butylphthalide sodium chloride injection combined with edaravone dexborneol on neurological function and serum inflammatory factor levels in sufferers having acute ischemic stroke, 120 sufferers having acute ischemic stroke from September 2020 to September 2021 are chosen for the study subjects."	8.12	Effects of Butylphthalide Sodium Chloride Injection Combined with Edaravone Dexborneol on Neurological Function and Serum Inflammatory Factor Levels in Sufferers Having Acute Ischemic Stroke. ( Li, K; Lu, X; Yao, S; Zhang, Q, 2022)
"Background and Purpose- Although several clinical studies suggested the beneficial effects of edaravone in acute ischemic stroke, most were performed under settings that differ from those in the current treatment strategy, which has dramatically changed with progress in reperfusion therapies."	7.91	Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. ( Endo, A; Enomoto, M; Fushimi, K; Otomo, Y; Yatsushige, H, 2019)
"Background and Purpose- In Japan, nearly half of ischemic stroke patients receive edaravone for acute treatment."	7.91	Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. ( Fukuhara, S; Fukuma, S; Ikenoue, T; Kobayashi, S, 2019)
"Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2."	7.88	Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018)
"Uric acid (UA), an antioxidant with neuroprotective effects, favorably affects stroke outcome."	7.88	Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone. ( Ando, Y; Inatomi, Y; Naganuma, M; Nakajima, M; Yonehara, T, 2018)
"Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset."	7.85	Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017)
"Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents."	7.81	Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015)
" The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke."	7.81	The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. ( Ishii, H; Sakamoto, K; Sato, T; Yamamoto, J; Yamashita, T, 2015)
"Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models."	7.80	Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014)
"We investigated whether edaravone could improve early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator (rtPA)."	7.80	Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. ( Fushimi, K; Horiguchi, H; Inokuchi, R; Matsubara, T; Nakajima, S; Wada, T; Yahagi, N; Yasunaga, H, 2014)
"One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone."	7.79	Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013)
"A free radical scavenger, edaravone, which has been used for the treatment of ischemic stroke, was reported to cause acute kidney injury (AKI) as a fatal adverse event."	7.79	Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013)
"A novel free radical scavenger, edaravone, has been demonstrated to exert a neuroprotective effect and improve outcomes in acute ischemic stroke, but there have been few clinical studies."	7.79	Investigation of effect of edaravone on ischemic stroke. ( Adachi, H; Ishibashi, A; Yoshitake, Y, 2013)
" The present study was undertaken to examine whether or not the free radical scavenger, edaravone, could prevent the extravasation of tPA administered for the purpose of fibrinolysis in a rat model of thromboembolic stroke."	7.73	Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. ( Harada, T; Kano, T; Katayama, Y, 2005)
"A male patient with rheumatoid arthritis (RA) developed acute stroke and was treated with the free radical scavenger, edaravone."	7.73	Edaravone inhibits the disease activity in rheumatoid arthritis. ( Arii, K; Hashimoto, K; Ikeda, Y; Kumon, Y; Suehiro, T, 2006)
"Salvianolic acid A (SAA) has shown neuroprotective effects against ischemic diseases."	5.72	Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3β/β-catenin signaling pathway. ( Du, GH; Jiang, N; Kong, DW; Kong, LL; Liu, CD; Liu, S; Ma, GD; Pan, ZR; Yang, YJ; Zhang, S; Zhang, W, 2022)
"The treatment of acute ischemic stroke (AIS) remains a tough challenge in clinic."	5.72	Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluro-edaravone as potential anti-acute ischemic stroke agents. ( Huang, Z; Ji, D; Jia, J; Jiao, W; Wang, X; Wu, J; Zhang, Y, 2022)
"Eighty-one patients with T2DM combined with CS who attended our hospital and received rehabilitation treatment from March 2020 to May 2021 were enrolled to a prospective nonrandomized controlled analysis."	5.72	Significance of Edaravone Combined with Emotion Management Model in Promoting the Recovery Process and Improving Negative Psychology in Patients with Type 2 Diabetes Mellitus Combined with Stroke. ( Lu, X; Lv, X, 2022)
" Although EDV promotes ischemic recovery by inhibiting the generation of ROS, its poor safety and bioavailability limit its clinical applications."	5.62	A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke. ( Guo, L; Li, F; Pan, J; Shi, Y; Zhao, L, 2021)
"Edaravone (Edv) can inhibit tissue damage, cause cerebral edema, and delay neuronal death caused by acute cerebral infarction."	5.56	Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020)
"This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI)."	5.51	The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction. ( Shen, QQ; Tong, XW; Wang, W; Wu, H, 2022)
" Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined."	5.41	Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. ( Li, LD; Shi, SF; Zhou, Y, 2023)
"This study aimed to explore how butylphthalide and edaravone promote healing in acute stroke, drawing on relevant data, literature, clinical experience, and personal concepts."	5.41	Clinical Efficacy and Short-Term Prognosis of Butylphthalide and Sodium Chloride Injection Compared to Edaravone in the Treatment of Patients with Acute Stroke. ( Wang, X; Yang, D; Zhang, J; Zhang, M, 2023)
"We performed a randomized clinical trial protocol to assess the effectiveness of edaravone for acute stroke."	5.41	Safety and efficacy of edaravone for patients with acute stroke: A protocol for randomized clinical trial. ( Cheng, X; Dou, Z; Jiao, G; Shan, H, 2021)
"Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect."	5.40	The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014)
" No adverse events were observed."	5.38	Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012)
"Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits."	5.38	Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012)
"Edaravone was originally developed as a potent free radical scavenger and, since 2001, has been widely used to treat AIS in Japan."	5.36	Edaravone: a new therapeutic approach for the treatment of acute stroke. ( Arimura, S; Hashiguchi, T; Kawahara, K; Kikuchi, K; Kuramoto, T; Maenosono, R; Maruyama, I; Matsuda, F; Mera, K; Miura, N; Miyagi, N; Morimoto, Y; Ohno, Y; Oyama, Y; Shigemori, M; Shrestha, B; Tada, K; Takenouchi, K; Tancharoen, S; Uchikado, H; Yoshida, Y; Yoshinaga, N, 2010)
"Edaravone is a lipophilic drug with multiple mechanisms of action."	5.35	The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2009)
" Here we analyzed the clinical outcomes of acute ischemic stroke (AIS) patients treated with human urinary kallidinogenase (HUK) or edaravone (Eda) combined with butylphthalide (NBP)."	5.30	Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke. ( Jiang, M; Lu, S; Lyu, Y; Nie, T; Qian, Y; Tang, B, 2019)
"While the addition of low dose chlorpromazine and promethazine to standard of care for acute ischemic stroke did not have any significant improvement in functional outcomes, there were no serious adverse effects."	5.30	Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. ( Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)
"To test the hypothesis that edaravone reduces functional dependence in ischemic stroke patients."	5.22	Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022)
" The aim of this meta-analysis was to determine the efficacy and tolerability of edaravone, with or without thrombolytic therapy, in the treatment of patients with acute ischemic stroke."	5.22	Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. ( Li, GZ; Nie, LY; Ye, XM; Zhao, K; Zhu, GY, 2022)
"A randomized, double-blind, placebo-controlled study was performed to prospectively evaluate the effects of edaravone on acute diabetic stroke patients admitted to our hospital within 24 h of stroke onset."	5.22	Edaravone offers neuroprotection for acute diabetic stroke patients. ( Chen, X; Zheng, J, 2016)
"We evaluated the influence of smoking on 90-day outcomes after acute atherothrombotic stroke in 292 Japanese men extracted from the database of the Edaravone and Argatroban Stroke Therapy for Acute Ischemic Stroke randomized parallel-group trial that tested the safety and efficacy of edaravone and argatroban therapy in 814 patients in 2004-2008."	5.17	Effects of smoking on outcomes after acute atherothrombotic stroke in Japanese men. ( Fujimoto, Y; Iiyama, T; Kawanishi, Y; Kumagai, N; Okuhara, Y; Origasa, H; Takekawa, H; Yamaguchi, T, 2013)
"MCI-186 (edaravone) is a free radical scavenger approved in Japan since 2001 for the treatment of patients with acute ischemic stroke within 24 h from the onset of symptoms."	5.17	Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. ( Dippel, DW; Ford, GA; Kaste, M; Murayama, S; Tatlisumak, T; Walters, MR, 2013)
"To identify prognostic factors affecting outcomes at 90 days after stroke from the viewpoint of recovery patterns, we enrolled 660 patients from the Edaravone and Argatroban Stroke Therapy for Acute Ischemic Stroke study database."	5.17	Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset. ( Kumagai, N; Nagao, T; Okuhara, Y; Origasa, H; Takekawa, H; Yamaguchi, T, 2013)
"Two new neuro-protective agents, Edaravone and Citicoline were recently found to be beneficial in acute ischemic stroke (AIS)."	5.16	Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012)
"The aim of the present study was to investigate whether administration of edaravone during t-PA infusion can enhance early recanalization in acute stroke patients."	5.16	Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study. ( Aoki, J; Iguchi, Y; Inoue, T; Kimura, K; Kobayashi, K; Sakai, K; Sakamoto, Y; Shibazaki, K, 2012)
" In this study, the temporal profile of ischemic stroke lesion sizes was assessed for more than one year to evaluate the effect of edaravone which might reduce ischemic damage."	5.15	Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. ( Nakase, T; Suzuki, A; Yoshioka, S, 2011)
"Edaravone, a free radical scavenger approved by the Japanese Ministry of Health, Labor and Welfare in 2001 for treating acute ischemic stroke, was recommended by the Japanese Guidelines for the Management of Stroke 2004."	5.14	Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). ( Kobayashi, S; Saito, I; Shinohara, Y; Uchiyama, S, 2009)
"Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients."	5.14	Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010)
"Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients."	5.12	Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis. ( Chen, LQ; Guan, B; Li, Y; Ming, Q; Yang, DX; Yu, D, 2021)
"The efficacy of hyperbaric oxygen (HBO) therapy combined with intravenous edaravone (free radical scavenger) administration was prospectively investigated in patients with acute embolic stroke involving the anterior cerebral circulation."	5.12	Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial. ( Imai, K; Izumoto, H; Kunieda, T; Mori, T; Takabatake, N; Watanabe, M, 2006)
" The same molecule is also known as edaravone, a drug approved for the treatment of stroke and amyotrophic lateral sclerosis."	5.05	Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone. ( Bailly, C; Goossens, JF; Hecquet, PE; Kouach, M; Thuru, X, 2020)
"To assess the effectiveness of edaravone for acute stroke including ischemic stroke and intracerebral hemorrhage (ICH)."	4.91	Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. ( Cui, X; Li, J; Liu, M; Yang, J; Zhang, C; Zhang, J, 2015)
"Radical scavenger compounds (such as Ebselen and Edaravone) are under clinical investigation as a therapeutic approach against stroke."	4.91	Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. ( Braunersreuther, V; Carbone, F; Mach, F; Montecucco, F; Teixeira, PC; Vuilleumier, N, 2015)
"Outcome of efficacy of therapies for acute ischemic stroke are as followed: All of the therapies mentioned above yielded results a more effective result than placebo, Sodium ozagrel (RR 3."	4.90	Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. ( Chen, X; Ma, B; Shi, J; Sun, H; Yang, B, 2014)
"Edaravone was originally developed as a potent free radical scavenger, and has been widely used to treat acute ischemic stroke in Japan since 2001."	4.89	The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. ( Kikuchi, K; Morioka, M; Murai, Y; Takeshige, N; Tanaka, E; Tancharoen, S; Yoshitomi, M, 2013)
"To assess the efficacy and safety of edaravone for acute ischaemic stroke."	4.87	Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011)
"Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually."	4.86	A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010)
"A free radical scavenger Edaravone is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA)."	4.84	[Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy]. ( Abe, K, 2008)
" Four compounds with free radical scavenging activity (tirilazad, ebselen, edaravone) or free radical trapping properties (NXY-059) have been examined in experimental models of stroke and evaluated clinically as neuroprotective agents."	4.82	Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. ( Ashwood, T; Green, AR, 2005)
" Only three drugs, nicaravene, ebselen and edaravone, all radical scavengers, were judged effective by small-sized trials with a wide therapeutic window, 48-72 hours after stroke, in Japan."	4.81	[Neuroprotective therapy for the treatment of acute ischemic stroke]. ( Naritomi, H, 2001)
"To investigate the efficacy of butylphthalide combined with edaravone in the treatment of acute ischemic stroke and the effect on serum inflammatory factors."	4.31	Efficacy of Butylphthalide in Combination with Edaravone in the Treatment of Acute Ischemic Stroke and the Effect on Serum Inflammatory Factors. ( Hong, Z; Li, S; Li, Y; Liu, Y; Wang, J; Xie, S, 2023)
"DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment."	4.31	A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023)
"For investigating an influence on butylphthalide sodium chloride injection combined with edaravone dexborneol on neurological function and serum inflammatory factor levels in sufferers having acute ischemic stroke, 120 sufferers having acute ischemic stroke from September 2020 to September 2021 are chosen for the study subjects."	4.12	Effects of Butylphthalide Sodium Chloride Injection Combined with Edaravone Dexborneol on Neurological Function and Serum Inflammatory Factor Levels in Sufferers Having Acute Ischemic Stroke. ( Li, K; Lu, X; Yao, S; Zhang, Q, 2022)
"Background and Purpose- Although several clinical studies suggested the beneficial effects of edaravone in acute ischemic stroke, most were performed under settings that differ from those in the current treatment strategy, which has dramatically changed with progress in reperfusion therapies."	3.91	Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. ( Endo, A; Enomoto, M; Fushimi, K; Otomo, Y; Yatsushige, H, 2019)
"Background and Purpose- In Japan, nearly half of ischemic stroke patients receive edaravone for acute treatment."	3.91	Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. ( Fukuhara, S; Fukuma, S; Ikenoue, T; Kobayashi, S, 2019)
"Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2."	3.88	Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018)
"Uric acid (UA), an antioxidant with neuroprotective effects, favorably affects stroke outcome."	3.88	Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone. ( Ando, Y; Inatomi, Y; Naganuma, M; Nakajima, M; Yonehara, T, 2018)
"Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset."	3.85	Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017)
"Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents."	3.81	Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015)
" Previous studies have demonstrated that the free radical scavenger edaravone may prevent neuronal injury and brain edema after ICH."	3.81	The radical scavenger edaravone improves neurologic function and perihematomal glucose metabolism after acute intracerebral hemorrhage. ( Cui, D; Liang, S; Shang, H; Yang, D; Zhang, W; Zhao, W, 2015)
" The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke."	3.81	The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. ( Ishii, H; Sakamoto, K; Sato, T; Yamamoto, J; Yamashita, T, 2015)
"Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models."	3.80	Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014)
"We investigated whether edaravone could improve early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator (rtPA)."	3.80	Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. ( Fushimi, K; Horiguchi, H; Inokuchi, R; Matsubara, T; Nakajima, S; Wada, T; Yahagi, N; Yasunaga, H, 2014)
"One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone."	3.79	Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013)
"A free radical scavenger, edaravone, which has been used for the treatment of ischemic stroke, was reported to cause acute kidney injury (AKI) as a fatal adverse event."	3.79	Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013)
"A novel free radical scavenger, edaravone, has been demonstrated to exert a neuroprotective effect and improve outcomes in acute ischemic stroke, but there have been few clinical studies."	3.79	Investigation of effect of edaravone on ischemic stroke. ( Adachi, H; Ishibashi, A; Yoshitake, Y, 2013)
"Edaravone, a drug for treating acute ischemic stroke, has been reported to provoke acute renal disorders."	3.75	Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. ( Hishida, A, 2009)
"A retrospective review was carried out of 207 Japanese patients with acute stroke who developed renal disorders on edaravone treatment."	3.74	Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. ( Hishida, A, 2007)
" The present study was undertaken to examine whether or not the free radical scavenger, edaravone, could prevent the extravasation of tPA administered for the purpose of fibrinolysis in a rat model of thromboembolic stroke."	3.73	Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. ( Harada, T; Kano, T; Katayama, Y, 2005)
"A male patient with rheumatoid arthritis (RA) developed acute stroke and was treated with the free radical scavenger, edaravone."	3.73	Edaravone inhibits the disease activity in rheumatoid arthritis. ( Arii, K; Hashimoto, K; Ikeda, Y; Kumon, Y; Suehiro, T, 2006)
"In the last few decades, medical treatment for stroke has made progress greatly."	2.53	[History and current status of medical treatment for stroke]. ( Yagita, Y, 2016)
"Edaravone was approved in Japan for the treatment of acute brain infarction within 24 h after onset in April, 2001."	2.41	[Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent]. ( Tanaka, M, 2002)
"Salvianolic acid A (SAA) has shown neuroprotective effects against ischemic diseases."	1.72	Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3β/β-catenin signaling pathway. ( Du, GH; Jiang, N; Kong, DW; Kong, LL; Liu, CD; Liu, S; Ma, GD; Pan, ZR; Yang, YJ; Zhang, S; Zhang, W, 2022)
"Edaravone combined with anticoagulant therapy is a reliable method to enhance ADL and reduce the inflammatory response of ACI patients."	1.72	Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF- ( Ma, C; Ma, L; Sun, C; Sun, Y, 2022)
"The treatment of acute ischemic stroke (AIS) remains a tough challenge in clinic."	1.72	Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluro-edaravone as potential anti-acute ischemic stroke agents. ( Huang, Z; Ji, D; Jia, J; Jiao, W; Wang, X; Wu, J; Zhang, Y, 2022)
"Eighty-one patients with T2DM combined with CS who attended our hospital and received rehabilitation treatment from March 2020 to May 2021 were enrolled to a prospective nonrandomized controlled analysis."	1.72	Significance of Edaravone Combined with Emotion Management Model in Promoting the Recovery Process and Improving Negative Psychology in Patients with Type 2 Diabetes Mellitus Combined with Stroke. ( Lu, X; Lv, X, 2022)
" Although EDV promotes ischemic recovery by inhibiting the generation of ROS, its poor safety and bioavailability limit its clinical applications."	1.62	A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke. ( Guo, L; Li, F; Pan, J; Shi, Y; Zhao, L, 2021)
"Edaravone (Edv) can inhibit tissue damage, cause cerebral edema, and delay neuronal death caused by acute cerebral infarction."	1.56	Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020)
"Rat transient middle cerebral artery occlusion (MCAO) model was established."	1.43	Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. ( Chen, J; Ding, WS; Ding, XS; Liu, XF; Shen, HC; Shen, LH; Sheng, YF; Ye, M, 2016)
"Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect."	1.40	The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014)
" No adverse events were observed."	1.38	Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012)
"Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits."	1.38	Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012)
"Stroke is an enormous public health problem with an imperative need for more effective therapy."	1.37	Translational stroke research of the combination of thrombolysis and antioxidant therapy. ( Amaro, S; Chamorro, Á, 2011)
"Edaravone was originally developed as a potent free radical scavenger and, since 2001, has been widely used to treat AIS in Japan."	1.36	Edaravone: a new therapeutic approach for the treatment of acute stroke. ( Arimura, S; Hashiguchi, T; Kawahara, K; Kikuchi, K; Kuramoto, T; Maenosono, R; Maruyama, I; Matsuda, F; Mera, K; Miura, N; Miyagi, N; Morimoto, Y; Ohno, Y; Oyama, Y; Shigemori, M; Shrestha, B; Tada, K; Takenouchi, K; Tancharoen, S; Uchikado, H; Yoshida, Y; Yoshinaga, N, 2010)
"Edaravone is a lipophilic drug with multiple mechanisms of action."	1.35	The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2009)

Research

Studies (83)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (20.48)	29.6817
2010's	42 (50.60)	24.3611
2020's	24 (28.92)	2.80

Authors

Authors	Studies
Sun, Y	2
Jiang, J	1
Zhang, Z	1
Yu, P	1
Wang, L	2
Xu, C	1
Liu, W	1
Wang, Y	1
Wu, J	3
Ling, J	1
Wang, X	5
Li, T	1
Liu, J	1
Lai, Y	1
Ji, H	2
Peng, S	1
Tian, J	1
Zhang, Y	4
Sheng, X	1
Hua, K	1
Yang, C	1
Xu, J	1
Huang, Z	2
Huang, L	1
Wang, J	3
Chen, L	1
Zhu, M	1
Wu, S	1
Chu, S	2
Zheng, Y	1
Fan, Z	1
Zhang, J	3
Li, W	3
Chen, D	1
Yang, X	1
Wang, S	1
Qiu, P	1
Zang, Y	1
Song, X	1
Li, C	1
Ma, J	1
Liu, D	1
Ren, Q	1
Li, Y	5
Chen, N	1
Zhang, D	1
Bailly, C	1
Hecquet, PE	1
Kouach, M	1
Thuru, X	1
Goossens, JF	1
Marco-Contelles, J	1
Wang, H	1
Cui, E	1
Li, J	3
Ma, X	1
Jiang, X	1
Du, S	1
Qian, S	1
Du, L	1
Guo, L	1
Pan, J	1
Li, F	2
Zhao, L	2
Shi, Y	2
Yang, DX	1
Yu, D	1
Guan, B	1
Ming, Q	1
Chen, LQ	1
Zhang, S	2
Kong, DW	1
Ma, GD	1
Liu, CD	1
Yang, YJ	1
Liu, S	1
Jiang, N	1
Pan, ZR	1
Zhang, W	2
Kong, LL	1
Du, GH	1
Sun, C	1
Ma, C	1
Ma, L	1
Li, K	1
Zhang, Q	1
Lu, X	2
Yao, S	1
Song, MM	1
Chen, J	2
Ye, SM	1
Lu, DP	1
Zhang, GY	1
Liu, R	1
Shen, YX	1
Fidalgo, M	1
Ricardo Pires, J	1
Viseu, I	1
Magalhães, P	1
Gregório, H	1
Afreixo, V	1
Gregório, T	1
Jia, J	1
Ji, D	1
Jiao, W	1
Huang, Y	1
Zhang, X	2
Zhang, C	2
Xu, W	1
Feng, Z	1
Zhao, K	3
Lv, X	1
Shen, QQ	1
Wang, W	1
Wu, H	1
Tong, XW	1
Li, GZ	2
Nie, LY	2
Ye, XM	2
Zhu, GY	2
Yasutaka, Y	1
Fujioka, S	1
Tsuboi, Y	1
Oyabu, K	1
Shibaguchi, H	1
Kamimura, H	1
Li, LD	1
Zhou, Y	1
Shi, SF	1
Hong, Z	1
Li, S	1
Xie, S	1
Liu, Y	1
Zhang, H	1
Zhu, B	1
Yang, Y	1
Cai, C	1
Deng, L	1
He, B	1
Cui, Y	1
Zhou, W	1
Yang, D	3
Zhang, M	1
Qian, Y	1
Lyu, Y	1
Jiang, M	1
Tang, B	1
Nie, T	1
Lu, S	1
Liang, J	1
Shan, H	1
Jiao, G	1
Cheng, X	1
Dou, Z	1
Vdovychenko, YP	1
Loskutov, OA	1
Halushko, OA	1
Trishchynska, MA	1
Dziuba, DO	1
Povietkina, TM	1
Vitiuk, AD	1
Tanahashi, N	4
Yamaguchi, T	4
Awano, H	2
Matsuda, H	2
Naganuma, M	1
Inatomi, Y	2
Nakajima, M	1
Yonehara, T	2
Ando, Y	1
Enomoto, M	1
Endo, A	1
Yatsushige, H	1
Fushimi, K	2
Otomo, Y	1
Zhu, H	1
Chandra, A	1
Geng, X	1
Cheng, Z	1
Tong, Y	1
Du, H	1
Ding, Y	1
Kobayashi, S	3
Fukuma, S	1
Ikenoue, T	1
Fukuhara, S	1
Wang, D	1
Peng, X	1
Yang, A	1
He, Y	1
Dong, L	1
Lu, H	1
Kono, S	1
Deguchi, K	1
Morimoto, N	1
Kurata, T	1
Yamashita, T	2
Ikeda, Y	2
Narai, H	1
Manabe, Y	1
Takao, Y	1
Kawada, S	1
Kashihara, K	1
Takehisa, Y	1
Inoue, S	1
Kiriyama, H	1
Abe, K	3
Mitta, M	1
Goel, D	1
Bansal, KK	1
Puri, P	1
Kamouchi, M	1
Sakai, H	1
Kiyohara, Y	1
Minematsu, K	1
Hayashi, K	1
Kitazono, T	1
Kikuchi, K	2
Tancharoen, S	2
Takeshige, N	1
Yoshitomi, M	1
Morioka, M	1
Murai, Y	1
Tanaka, E	1
Yang, J	1
Cui, X	1
Liu, M	2
Kumagai, N	2
Okuhara, Y	2
Iiyama, T	1
Fujimoto, Y	1
Takekawa, H	2
Origasa, H	2
Kawanishi, Y	1
Kaste, M	1
Murayama, S	1
Ford, GA	1
Dippel, DW	1
Walters, MR	1
Tatlisumak, T	1
Ishibashi, A	1
Yoshitake, Y	1
Adachi, H	1
Yang, B	1
Shi, J	1
Chen, X	2
Ma, B	1
Sun, H	1
Carbone, F	1
Teixeira, PC	1
Braunersreuther, V	1
Mach, F	1
Vuilleumier, N	1
Montecucco, F	1
Hashimoto, T	1
Shibata, K	1
Ohata, H	1
Hasumi, K	1
Honda, K	1
Sun, YY	1
Morozov, YM	1
Dunn, RS	1
Rakic, P	1
Chan, PH	1
Lindquist, DM	1
Kuan, CY	1
Wu, HY	1
Tang, Y	1
Gao, LY	1
Sun, WX	1
Hua, Y	1
Yang, SB	1
Zhang, ZP	1
Liao, GY	1
Zhou, QG	1
Luo, CX	1
Zhu, DY	1
Wada, T	1
Yasunaga, H	1
Inokuchi, R	1
Horiguchi, H	1
Matsubara, T	1
Nakajima, S	1
Yahagi, N	1
Shang, H	1
Cui, D	1
Liang, S	1
Zhao, W	1
Aoyama, Y	1
Ohta, S	1
Sakaki, S	1
Nishizawa, S	1
Fujita, T	1
Suzuki, Y	2
Hirano, T	1
Sato, T	1
Sakamoto, K	1
Ishii, H	1
Yamamoto, J	1
Zheng, J	1
Shen, LH	1
Shen, HC	1
Ye, M	1
Liu, XF	1
Ding, WS	1
Sheng, YF	1
Ding, XS	1
Yagita, Y	1
Lapchak, PA	2
Zivin, JA	1
Hishida, A	2
Shinohara, Y	2
Saito, I	1
Uchiyama, S	1
Kawahara, K	1
Miyagi, N	1
Uchikado, H	1
Kuramoto, T	1
Morimoto, Y	1
Miura, N	1
Takenouchi, K	1
Oyama, Y	1
Shrestha, B	1
Matsuda, F	1
Yoshida, Y	1
Arimura, S	1
Mera, K	1
Tada, K	1
Yoshinaga, N	1
Maenosono, R	1
Ohno, Y	1
Hashiguchi, T	1
Maruyama, I	1
Shigemori, M	1
Naritomi, H	2
Moriwaki, H	1
Metoki, N	1
Nishimura, H	1
Higashi, Y	1
Yamamoto, Y	1
Yuasa, H	1
Oe, H	1
Tanaka, K	1
Saito, K	1
Terayama, Y	1
Oda, T	1
Kondo, H	1
Baba, H	1
Sugimori, H	1
Nanishi, E	1
Nagata, H	1
Lee, S	1
Kuwashiro, T	1
Hashizume, M	1
Nakase, T	1
Yoshioka, S	1
Suzuki, A	1
Amaro, S	1
Chamorro, Á	1
Srinivasan, K	1
Sharma, SS	1
Kimura, K	1
Aoki, J	1
Sakamoto, Y	1
Kobayashi, K	1
Sakai, K	1
Inoue, T	1
Iguchi, Y	1
Shibazaki, K	1
Feng, S	1
Yang, Q	1
Yuan, W	1
Wu, B	1
Nagao, T	1
Green, AR	1
Ashwood, T	1
Kano, T	1
Harada, T	1
Katayama, Y	1
Arii, K	1
Kumon, Y	1
Suehiro, T	1
Hashimoto, K	1
Shima, K	1
Imai, K	1
Mori, T	1
Izumoto, H	1
Takabatake, N	1
Kunieda, T	1
Watanabe, M	1
Watanabe, T	1
Tahara, M	1
Todo, S	1
Umemura, K	1
Tanaka, M	1

Clinical Trials (5)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke[NCT00821821]	Phase 2	36 participants (Actual)	Interventional	2009-02-28	Completed
Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury[NCT03968042]	Phase 2	150 participants (Anticipated)	Interventional	2019-06-30	Recruiting
Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke[NCT00200356]	Phase 4	401 participants (Actual)	Interventional	2004-08-31	Completed
Randomized, Double Blind Study Assessing the Clinical Efficacy of Combined Treatment With Uric Acid and rtPA Administered Intravenously in Acute Ischemic Stroke Patients Within the First 4.5 Hours of Symptoms Onset[NCT00860366]	Phase 2/Phase 3	421 participants (Actual)	Interventional	2011-06-30	Completed
Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy[NCT00153946]	Phase 4	814 participants (Actual)	Interventional	2004-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Plasma MCI-186 Pharmacokinetics

The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined. (NCT00821821)
Timeframe: 72 hours

Intervention	ng / ml (Geometric Mean)
MCI-186 Cohort1	391
MCI-186 Cohort2	1595

Number of Participants That Experienced Adverse Events

Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency. (NCT00821821)
Timeframe: 87days

Intervention	participants (Number)
	Deaths	Serious Adverse Events	Other Adverse Events
MCI-186 Cohort1	0	0	12
MCI-186 Cohort2	0	2	10
Placebo Group	0	1	10

Barthel Index Score

"The Barthel Index of Activities of Daily Living measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state.~The number of patients with 95-100 Barthel Index was evaluated at at 3 months after treatment initiation." (NCT00200356)
Timeframe: 3 months

Intervention	participants (Number)
Edaravone	148
Ozagrel	133

Baseline NIH Stroke Scale Score

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). (NCT00200356)
Timeframe: Before treatment initiation

Intervention	scores on a scale (Mean)
Edaravone	3.7
Ozagrel	3.8

Japan Stroke Scale (Motor Function) Score at 1 Month

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 1 month after treatment initiation. (NCT00200356)
Timeframe: 1 month

Intervention	units on a scale (Mean)
Edaravone	3.632
Ozagrel	3.680

Japan Stroke Scale (Motor Function) Score at 14 Days

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 14 days after treatment initiation. (NCT00200356)
Timeframe: 14 days

Intervention	units on a scale (Mean)
Edaravone	4.521
Ozagrel	4.686

Japan Stroke Scale (Motor Function) Score at 3 Months

The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 3 months after treatment initiation. (NCT00200356)
Timeframe: 3 months

Intervention	units on a scale (Mean)
Edaravone	2.507
Ozagrel	2.927

Modified Rankin Scale Score

The number of patients with an Modified Rankin Scale score of 0-1 was evaluated at 6 months after treatment initiation. The Modified Rankin Scale has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability. (NCT00200356)
Timeframe: 6 months

Intervention	participants (Number)
Edaravone	112
Ozagrel	108

NIH Stroke Scale Score at 1 Month

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 1 month after treatment initiation. (NCT00200356)
Timeframe: 1 month

Intervention	participants (Number)
Edaravone	117
Ozagrel	119

NIH Stroke Scale Score at 14 Days

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 14 days after treatment initiation. (NCT00200356)
Timeframe: 14 days

Intervention	participants (Number)
Edaravone	98
Ozagrel	108

NIH Stroke Scale Score at 3 Months

The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 3 months after treatment initiation. (NCT00200356)
Timeframe: 3 months

Intervention	participants (Number)
Edaravone	135
Ozagrel	140

the Rate of Patients With a Modified Rankin Scale Score of 0-1

The number of patients with mRS score of 0-1 (good outcome) at 3 months after treatment initiation. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability. (NCT00200356)
Timeframe: 3 months

Intervention	participants (Number)
	Score(0-1)	0	1	2	3	4	5	Death
Edaravone	109	46	63	37	22	19	2	2
Ozagrel	98	39	59	40	29	24	3	1

Reviews

21 reviews available for edaravone and Stroke

Article	Year
Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone. Bioorganic & medicinal chemistry, 2020, 05-15, Volume: 28, Issue:10 Topics: Amyotrophic Lateral Sclerosis; Edaravone; Humans; Molecular Structure; Neuroprotective Agents; Strok	2020
Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis. Brain and behavior, 2021, Volume: 11, Issue:12 Topics: Brain Ischemia; Edaravone; Humans; Ischemic Stroke; Stroke; Tissue Kallikreins; Treatment Outcome	2021
Edaravone for acute ischemic stroke - Systematic review with meta-analysis. Clinical neurology and neurosurgery, 2022, Volume: 219 Topics: Adult; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Intracranial Hemorrha	2022
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Clinical therapeutics, 2022, Volume: 44, Issue:12 Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke	2022
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Clinical therapeutics, 2022, Volume: 44, Issue:12 Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke	2022
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Clinical therapeutics, 2022, Volume: 44, Issue:12 Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke	2022
Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Clinical therapeutics, 2022, Volume: 44, Issue:12 Topics: Edaravone; Hemorrhage; Humans; Ischemic Stroke; Neuroprotective Agents; Stroke	2022
Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. Medicine, 2023, Mar-03, Volume: 102, Issue:9 Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Edaravone; Humans; Stroke	2023
Clinical Efficacy and Short-Term Prognosis of Butylphthalide and Sodium Chloride Injection Compared to Edaravone in the Treatment of Patients with Acute Stroke. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:7 Topics: Antipyrine; Edaravone; Humans; Sodium Chloride; Stroke; Treatment Outcome	2023
The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. International journal of molecular sciences, 2013, Jul-04, Volume: 14, Issue:7 Topics: Animals; Antipyrine; Cardiovascular Diseases; Edaravone; Free Radical Scavengers; Gene Expression; H	2013
Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. Developmental neurorehabilitation, 2015, Volume: 18, Issue:5 Topics: Antipyrine; Edaravone; Free Radical Scavengers; Humans; Randomized Controlled Trials as Topic; Strok	2015
Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. PloS one, 2014, Volume: 9, Issue:2 Topics: Aged; Antipyrine; Bayes Theorem; China; Coagulants; Drug Therapy, Combination; Edaravone; Fibrinolyt	2014
Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. Antioxidants & redox signaling, 2015, Aug-10, Volume: 23, Issue:5 Topics: Animals; Antioxidants; Antipyrine; Azoles; Brain; Edaravone; Humans; Isoindoles; Membrane Glycoprote	2015
[History and current status of medical treatment for stroke]. Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74, Issue:4 Topics: Anticoagulants; Antihypertensive Agents; Antipyrine; Edaravone; Fibrinolytic Agents; Humans; Hydroxy	2016
[Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:1 Topics: Antipyrine; Aortic Aneurysm, Thoracic; Aortic Dissection; Edaravone; Free Radical Scavengers; Humans	2009
[Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy]. Rinsho shinkeigaku = Clinical neurology, 2008, Volume: 48, Issue:11 Topics: Animals; Antipyrine; Cell- and Tissue-Based Therapy; Drug Therapy, Combination; Edaravone; Free Radi	2008
A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Animals; Antipyrine; Brain Ischemia; Drug Evaluation, Preclinical; Edaravone; Free Radical Scavenger	2010
Edaravone for acute ischaemic stroke. The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12 Topics: Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Neuroprotective Agents; Rand	2011
[Neuroprotective therapy for the treatment of acute ischemic stroke]. Rinsho shinkeigaku = Clinical neurology, 2001, Volume: 41, Issue:12 Topics: Animals; Antioxidants; Antipyrine; Clinical Trials as Topic; Edaravone; Free Radical Scavengers; Hum	2001
[Clinical guidelines for stroke]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Nov-10, Volume: 93, Issue:11 Topics: Anticoagulants; Antipyrine; Arginine; Aspirin; Brain Edema; Edaravone; Fibrinolytic Agents; Free Rad	2004
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Current drug targets. CNS and neurological disorders, 2005, Volume: 4, Issue:2 Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radica	2005
[Advanced medical therapy in patients with acute ischemic stroke]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2006, Volume: 127, Issue:6 Topics: Administration, Oral; Anticoagulants; Antipyrine; Arginine; Aspirin; Drug Design; Edaravone; Fibrino	2006
[The development of new drugs for acute stroke]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2000, Volume: 116, Issue:6 Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Antioxidants; Antipyrine; Aspirin; Clinical Trial	2000
[Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2002, Volume: 119, Issue:5 Topics: Animals; Antipyrine; Brain Edema; Clinical Trials as Topic; Depression, Chemical; Edaravone; Free Ra	2002

Trials

14 trials available for edaravone and Stroke

Article	Year
The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2022, Volume: 73, Issue:3 Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Edaravone; Humans; Interleukin-10; Phosphopyruva	2022
Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke. Brain and behavior, 2019, Volume: 9, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzofurans; Brain Ischemia; Drug Therapy, Combination; Edaravone; F	2019
Safety and efficacy of edaravone for patients with acute stroke: A protocol for randomized clinical trial. Medicine, 2021, Feb-26, Volume: 100, Issue:8 Topics: Activities of Daily Living; Cerebrovascular Circulation; Edaravone; Female; Free Radical Scavengers;	2021
Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. Journal of neurosurgical sciences, 2019, Volume: 63, Issue:3 Topics: Adult; Aged; Aspirin; Atorvastatin; Chlorpromazine; Double-Blind Method; Drug Therapy, Combination;	2019
Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). The Journal of the Association of Physicians of India, 2012, Volume: 60 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipyrine; Brain Ischemia; Cytidi	2012
Effects of smoking on outcomes after acute atherothrombotic stroke in Japanese men. Journal of the neurological sciences, 2013, Dec-15, Volume: 335, Issue:1-2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipyrine; Antithrombins; Arginine; Asian People; Body	2013
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon	2013
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon	2013
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon	2013
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon	2013
Edaravone offers neuroprotection for acute diabetic stroke patients. Irish journal of medical science, 2016, Volume: 185, Issue:4 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antipyrine; Diabetes Mellitus; Double-Blind Met	2016
Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovascular diseases (Basel, Switzerland), 2009, Volume: 27, Issue:5 Topics: Aged; Aged, 80 and over; Antipyrine; Edaravone; Female; Free Radical Scavengers; Humans; Japan; Male	2009
Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. Drugs in R&D, 2010, Volume: 10, Issue:3 Topics: Aged; Antipyrine; Brain Ischemia; Drug Administration Schedule; Edaravone; Female; Free Radical Scav	2010
Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. BMC neurology, 2011, Mar-30, Volume: 11 Topics: Activities of Daily Living; Aged; Antipyrine; Brain Infarction; Diffusion Magnetic Resonance Imaging	2011
Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study. Journal of the neurological sciences, 2012, Feb-15, Volume: 313, Issue:1-2 Topics: Aged; Aged, 80 and over; Antipyrine; Edaravone; Female; Free Radical Scavengers; Humans; Infusions,	2012
Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6 Topics: Aged; Aged, 80 and over; Antipyrine; Arginine; Brain Ischemia; Chi-Square Distribution; Disability E	2013
Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial. Neurologia medico-chirurgica, 2006, Volume: 46, Issue:8 Topics: Acute Disease; Aged; Antipyrine; Combined Modality Therapy; Edaravone; Emergency Medical Services; F	2006

Other Studies

48 other studies available for edaravone and Stroke

Article	Year
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorganic & medicinal chemistry, 2008, Oct-01, Volume: 16, Issue:19 Topics: Animals; Antioxidants; Brain Ischemia; Fibrinolytic Agents; Nitrogen Oxides; Pyrazines; Rats; Stroke	2008
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one. Journal of medicinal chemistry, 2012, Aug-23, Volume: 55, Issue:16 Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Fr	2012
Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. Bioorganic & medicinal chemistry letters, 2015, Sep-01, Volume: 25, Issue:17 Topics: Animals; Antipyrine; Benzofurans; Cell Line; Drug Design; Edaravone; Free Radical Scavengers; Humans	2015
Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents. European journal of medicinal chemistry, 2018, Jan-01, Volume: 143 Topics: Animals; Brain Ischemia; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Hydrogen Pero	2018
Pyrano[3,2-a]carbazole alkaloids as effective agents against ischemic stroke in vitro and in vivo. European journal of medicinal chemistry, 2018, Jan-01, Volume: 143 Topics: Alkaloids; Animals; Blood-Brain Barrier; Brain Ischemia; Carbazoles; Cell Survival; Cells, Cultured;	2018
From Seeds of Journal of medicinal chemistry, 2020, 11-12, Volume: 63, Issue:21 Topics: Animals; Apium; Asthma; Benzofurans; Brain Ischemia; Humans; Neuroprotective Agents; Seeds; Stereois	2020
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment. European journal of medicinal chemistry, 2022, Nov-05, Volume: 241 Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazol	2022
A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke. IET nanobiotechnology, 2021, Volume: 15, Issue:1 Topics: Brain; Brain Ischemia; Edaravone; Exosomes; Free Radical Scavengers; Humans; Ischemic Stroke; Stroke	2021
Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3β/β-catenin signaling pathway. Acta pharmacologica Sinica, 2022, Volume: 43, Issue:9 Topics: Animals; beta Catenin; Caffeic Acids; Edaravone; Glycogen Synthase Kinase 3 beta; Ischemic Stroke; L	2022
Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF- Journal of healthcare engineering, 2022, Volume: 2022 Topics: Anticoagulants; C-Reactive Protein; Cerebral Infarction; Edaravone; Humans; Interleukin-6; Retrospec	2022
Effects of Butylphthalide Sodium Chloride Injection Combined with Edaravone Dexborneol on Neurological Function and Serum Inflammatory Factor Levels in Sufferers Having Acute Ischemic Stroke. Journal of healthcare engineering, 2022, Volume: 2022 Topics: Benzofurans; Edaravone; Humans; Interleukin-6; Ischemic Stroke; Quality of Life; Sodium Chloride; St	2022
Targeted delivery of edaravone by liposomes for the treatment of ischemic stroke. Nanomedicine (London, England), 2022, Volume: 17, Issue:11 Topics: Animals; Brain; Edaravone; Ischemic Stroke; Liposomes; Rats; Stroke; Tissue Distribution	2022
Synthesis and biological evaluation of hybrids from optically active ring-opened 3-N-butylphthalide derivatives and 4-fluro-edaravone as potential anti-acute ischemic stroke agents. Bioorganic & medicinal chemistry, 2022, 09-01, Volume: 69 Topics: Animals; Benzofurans; Edaravone; Ischemic Stroke; Neuroprotective Agents; Rats; Stroke	2022
Edaravone Dexborneol Downregulates Neutrophil Extracellular Trap Expression and Ameliorates Blood-Brain Barrier Permeability in Acute Ischemic Stroke. Mediators of inflammation, 2022, Volume: 2022 Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Deoxyribonuclease I; Edaravone; Extracellular Traps; H	2022
Significance of Edaravone Combined with Emotion Management Model in Promoting the Recovery Process and Improving Negative Psychology in Patients with Type 2 Diabetes Mellitus Combined with Stroke. BioMed research international, 2022, Volume: 2022 Topics: Activities of Daily Living; Anxiety; Blood Glucose; Diabetes Mellitus, Type 2; Edaravone; Humans; Pr	2022
Liver toxicity of intravenous heparin treatment in patients with acute ischemic stroke. Clinical neurology and neurosurgery, 2023, Volume: 226 Topics: Anticoagulants; Cerebral Infarction; Edaravone; Enoxaparin; Heparin; Humans; Ischemic Stroke; Liver;	2023
Efficacy of Butylphthalide in Combination with Edaravone in the Treatment of Acute Ischemic Stroke and the Effect on Serum Inflammatory Factors. Disease markers, 2023, Volume: 2023 Topics: Benzofurans; Edaravone; Humans; Inflammation; Interleukin-6; Ischemic Stroke; Stroke	2023
A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. European journal of pharmacology, 2023, Jul-15, Volume: 951 Topics: Animals; Brain Ischemia; Edaravone; Infarction, Middle Cerebral Artery; Inflammation; Ischemic Strok	2023
Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. Molecular pharmaceutics, 2020, 09-08, Volume: 17, Issue:9 Topics: Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Exosomes; Infarction, Middle Cerebral Ar	2020
ACUTE ISCHEMIC STROKE IN WOMEN: EFFICACY OF THE FREE RADICAL SCAVENGER EDARAVONE. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2021, Volume: 74, Issue:1 Topics: Brain Ischemia; Edaravone; Female; Free Radical Scavengers; Humans; Ischemic Stroke; Prospective Stu	2021
Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:5 Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Diabetes Mellitus; Disability Evaluation; Disea	2018
Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone. Cerebrovascular diseases (Basel, Switzerland), 2018, Volume: 45, Issue:3-4 Topics: Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Disability Evaluation; Edaravone; Female; Free	2018
Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. Stroke, 2019, Volume: 50, Issue:3 Topics: Aged; Aged, 80 and over; Brain Ischemia; Cohort Studies; Combined Modality Therapy; Edaravone; Endov	2019
Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. Stroke, 2019, Volume: 50, Issue:7 Topics: Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Databases, Factual; Edaravone; Humans; Japa	2019
Edaravone promotes nerve function recovery after acute cerebral infarction in rats via targeting Keap1-Nrf2/ARE. Panminerva medica, 2021, Volume: 63, Issue:3 Topics: Animals; Brain Ischemia; Cerebral Infarction; Edaravone; Free Radical Scavengers; Kelch-Like ECH-Ass	2021
Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Edaravone; Female; Fibrinolytic Agents;	2013
Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:8 Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Case-Control Studies; Chi-	2013
Investigation of effect of edaravone on ischemic stroke. The Kurume medical journal, 2013, Volume: 60, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Arginine; Edaravone; Female; Free Radical Scavengers; Hu	2013
Altered gene expression in an embolic stroke model after thrombolysis with tissue plasminogen activator and Stachybotrys microspora triprenyl phenol-7. Journal of pharmacological sciences, 2014, Volume: 125, Issue:1 Topics: Animals; Antioxidants; Antipyrine; Benzopyrans; Calgranulin A; Disease Models, Animal; Edaravone; Fr	2014
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. PloS one, 2014, Volume: 9, Issue:6 Topics: Animals; Antipyrine; Cell Hypoxia; Disease Models, Animal; Drug Synergism; Edaravone; Humans; Hypoxi	2014
The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. European journal of pharmacology, 2014, Oct-05, Volume: 740 Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Brain; Brain Ischemia; Camphanes; Cell Survival; Cell	2014
Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. Journal of the neurological sciences, 2014, Oct-15, Volume: 345, Issue:1-2 Topics: Aged; Aged, 80 and over; Antipyrine; Databases, Factual; Edaravone; Female; Fibrinolytic Agents; Fre	2014
The radical scavenger edaravone improves neurologic function and perihematomal glucose metabolism after acute intracerebral hemorrhage. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:1 Topics: Animals; Antipyrine; Behavior, Animal; Body Water; Brain Edema; Cell Death; Edaravone; Fluorodeoxygl	2015
[Case of spontaneous cervical internal carotid artery dissection with embolic stroke after a job-change]. Journal of UOEH, 2014, Dec-01, Volume: 36, Issue:4 Topics: Antipyrine; Arginine; Carotid Artery, Internal, Dissection; Diagnosis, Differential; Edaravone; Huma	2014
[Dystypia after ischemic stroke: a disturbance of linguistic processing for Romaji (Romanized Japanese)?]. Rinsho shinkeigaku = Clinical neurology, 2015, Volume: 55, Issue:1 Topics: Aged; Agraphia; Anticoagulants; Antipyrine; Aphasia; Diffusion Magnetic Resonance Imaging; Drug Ther	2015
The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. Thrombosis research, 2015, Volume: 135, Issue:6 Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Fibrinolysis; Fibrinolytic Agents; Free Radi	2015
Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. Chinese medical journal, 2016, Jun-20, Volume: 129, Issue:12 Topics: Animals; Antipyrine; Bone Marrow Cells; Brain Ischemia; Chemokine CXCL12; Disease Models, Animal; Ed	2016
Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:4 Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Cohort Studies; Edaravone; Female; Fibrinolytic	2017
The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Experimental neurology, 2009, Volume: 215, Issue:1 Topics: Animals; Antipyrine; Behavior, Animal; Carotid Artery Thrombosis; Disease Models, Animal; Dose-Respo	2009
Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. Clinical and experimental nephrology, 2009, Volume: 13, Issue:2 Topics: Acute Kidney Injury; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Logisti	2009
Edaravone: a new therapeutic approach for the treatment of acute stroke. Medical hypotheses, 2010, Volume: 75, Issue:6 Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Humans; Neuroprotective Agents; Rats; Strok	2010
Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8 Topics: Antipyrine; Brain Ischemia; Child; Disability Evaluation; Drug Therapy, Combination; Edaravone; Fema	2012
Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke, 2011, Volume: 42, Issue:5 Topics: Antioxidants; Antipyrine; Biomarkers; Edaravone; Fibrinolytic Agents; Humans; Nitrogen Oxides; Oxida	2011
Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. Basic & clinical pharmacology & toxicology, 2012, Volume: 110, Issue:2 Topics: Animals; Antipyrine; Apoptosis; Caspase 12; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type	2012
Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. Neurological research, 2005, Volume: 27, Issue:5 Topics: Analysis of Variance; Animals; Antipyrine; Blood Vessels; Cerebral Hemorrhage; Disease Models, Anima	2005
Edaravone inhibits the disease activity in rheumatoid arthritis. Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:2 Topics: Antipyrine; Arthritis, Rheumatoid; C-Reactive Protein; Edaravone; Free Radical Scavengers; Humans; M	2006
Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clinical and experimental nephrology, 2007, Volume: 11, Issue:4 Topics: Aged; Aged, 80 and over; Antipyrine; Blood Urea Nitrogen; Creatinine; Edaravone; Female; Free Radica	2007
The novel antioxidant edaravone: from bench to bedside. Cardiovascular therapeutics, 2008,Summer, Volume: 26, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Drug Evaluation, Preclinical; Edaravone; Free Radical	2008

chemdatabank.com